Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Consensus and controversy of liquid biopsy using circulating tumour DNA (ctDNA) for molecular residual disease detection in colorectal cancer

This review summarizes evidence that postoperative ctDNA is a strong prognostic marker in colorectal cancer, while clinical utility remains incompletely established. It notes that ctDNA-informed management can reduce adjuvant chemotherapy use in selected stage II colon cancer, that non-inferiority has not been established in stage III disease, and that cytotoxic escalation for ctDNA-positive MRD has not improved recurrence-free survival. The authors conclude that, outside trials, ctDNA should refine prognosis rather than dictate omission, intensification, or initiation of treatment.

The Lancet Regional Health - Western PacificPubMed 42964788DOI 10.1016/j.lanwpc.2026.102001